These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38036041)

  • 1. Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma.
    Gan X; Dong W; You W; Ding D; Yang Y; Sun D; Li W; Ding W; Liang Y; Yang F; Zhou W; Dong H; Yuan S
    Cancer Lett; 2024 Jan; 581():216513. PubMed ID: 38036041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma.
    Gong W; Zhang S; Tian X; Chen W; He Y; Chen L; Ding T; Ren P; Shi L; Wu Q; Sun Y; Chen L; Guo H
    Hepatol Int; 2024 Aug; 18(4):1310-1325. PubMed ID: 38767772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
    Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
    Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q
    J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
    J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
    Nguyen CT; Caruso S; Maille P; Beaufrère A; Augustin J; Favre L; Pujals A; Boulagnon-Rombi C; Rhaiem R; Amaddeo G; di Tommaso L; Luciani A; Regnault H; Brustia R; Scatton O; Charlotte F; Brochériou I; Sommacale D; Soussan P; Leroy V; Laurent A; Le VK; Ta VT; Trinh HS; Tran TL; Gentien D; Rapinat A; Nault JC; Allaire M; Mulé S; Zucman-Rossi J; Pawlotsky JM; Tournigand C; Lafdil F; Paradis V; Calderaro J
    Clin Cancer Res; 2022 Feb; 28(3):540-551. PubMed ID: 34785581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.
    Ke K; Lin J; Huang N; Yan L; Liao R; Yang W
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1888. PubMed ID: 37688511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
    Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
    Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using immunovascular characteristics to predict very early recurrence and prognosis of resectable intrahepatic cholangiocarcinoma.
    Xu Y; Li Z; Zhou Y; Yang Y; Ouyang J; Li L; Huang Z; Ye F; Ying J; Zhao H; Zhou J; Zhao X
    BMC Cancer; 2023 Oct; 23(1):1009. PubMed ID: 37858111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
    Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma.
    Li Y; He D; Lu ZJ; Gu XF; Liu XY; Chen M; Tu YX; Zhou Y; Owen G; Zhang X; Jiang D
    BMC Cancer; 2024 Oct; 24(1):1232. PubMed ID: 39375615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
    Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
    J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
    J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.
    Zhang F; Hu K; Tang B; Tian M; Lu S; Yuan J; Li M; Chen R; Ren Z; Shi Y; Yin X
    J Gastrointest Surg; 2021 Apr; 25(4):971-982. PubMed ID: 32350718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification.
    Kim M; Hwang S; Ahn CS; Kim KH; Moon DB; Song GW; Jung DH; Hong SM
    Asian J Surg; 2021 Nov; 44(11):1389-1395. PubMed ID: 33766528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.